P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325
作者:Michael T. Rudd、John W. Butcher、Kevin T. Nguyen、Charles J. McIntyre、Joseph J. Romano、Kevin F. Gilbert、Kimberly J. Bush、Nigel J. Liverton、M. Katharine Holloway、Steven Harper、Marco Ferrara、Marcello DiFilippo、Vincenzo Summa、John Swestock、Jeff Fritzen、Steven S. Carroll、Christine Burlein、Jillian M. DiMuzio、Adam Gates、Donald J. Graham、Qian Huang、Stephanie McClain、Carolyn McHale、Mark W. Stahlhut、Stuart Black、Robert Chase、Aileen Soriano、Christine M. Fandozzi、Anne Taylor、Nicole Trainor、David B. Olsen、Paul J. Coleman、Steven W. Ludmerer、John A. McCauley
DOI:10.1002/cmdc.201402558
日期:2015.4
With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clinically relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK‐5172. Quinazolinone‐containing macrocycles were identified as promising leads, and optimization for superior cross‐genotype
为了确定对多种基因型和临床相关突变病毒有效的丙型肝炎病毒(HCV)NS3 / 4a蛋白酶抑制剂,基于发现MK‐5172期间的观察结果,研究了几个大环亚系列。含喹唑啉酮的大环化合物被认为是有前途的先导,口服给药后针对优异的交叉基因型和突变酶效力以及大鼠肝脏和血浆浓度的优化导致了MK-2748的发展。对包含稠合的18和15元环系统的一系列双大环的其他研究也针对相同的性质进行了优化,从而发现了MK-6325。